var data={"title":"Physiology and available preparations of melatonin","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Physiology and available preparations of melatonin</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/contributors\" class=\"contributor contributor_credentials\">Richard Wurtman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/contributors\" class=\"contributor contributor_credentials\">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/contributors\" class=\"contributor contributor_credentials\">Kathryn A Martin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 17, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Melatonin is a hormone produced in the pineal gland from the amino acid tryptophan and secreted into the blood and cerebrospinal fluid. It conveys signals to distant organs, principally the brain, and affects the synthesis of second messengers and, ultimately, sleep and circadian rhythms.</p><p>The physiology of melatonin and an overview of its clinical uses are reviewed here. Additional information on clinical uses of melatonin are found separately. (See <a href=\"topic.htm?path=treatment-of-insomnia-in-adults#H13\" class=\"medical medical_review\">&quot;Treatment of insomnia in adults&quot;, section on 'Melatonin agonists'</a> and <a href=\"topic.htm?path=jet-lag\" class=\"medical medical_review\">&quot;Jet lag&quot;</a> and <a href=\"topic.htm?path=complementary-and-alternative-therapies-for-cancer#H18\" class=\"medical medical_review\">&quot;Complementary and alternative therapies for cancer&quot;, section on 'Melatonin'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The human pineal gland is an important structure that transmits signals to the brain and other organs by secreting its unique hormone, melatonin. However, this concept is only a few decades old. In 1975, it was discovered that melatonin production in humans, like that in all other mammals studied, exhibits a pronounced circadian rhythm such that nocturnal plasma melatonin concentrations are at least 10-fold higher than daytime concentrations [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In humans, nocturnal serum concentrations of melatonin decline across puberty [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/3\" class=\"abstract_t\">3</a>], but no reproductive effects of exogenous melatonin have been clearly demonstrated [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Much pineal research has concerned the human brain's responses to melatonin rhythms. The most compelling evidence supports two roles for melatonin in humans: the involvement of nocturnal melatonin secretion in initiating and maintaining sleep, and control by the <span class=\"nowrap\">day/night</span> melatonin rhythm of the timing of other 24-hour rhythms. Melatonin's effect on sleep underlies most of its current use as a drug and the development of melatonin analogs as new drugs [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/5,6\" class=\"abstract_t\">5,6</a>]. (See <a href=\"#H14100125\" class=\"local\">'Circadian rhythm'</a> below and <a href=\"#H722736473\" class=\"local\">'Melatonin agonists'</a> below.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">MELATONIN PHYSIOLOGY</span></p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Synthesis and metabolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Almost all of the melatonin formed in mammals is synthesized within the pineal gland from the essential amino acid tryptophan (<a href=\"image.htm?imageKey=ENDO%2F77541\" class=\"graphic graphic_figure graphicRef77541 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/7\" class=\"abstract_t\">7</a>]. Plasma melatonin and its circadian rhythm largely or completely disappear among pinealectomized animals [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/8\" class=\"abstract_t\">8</a>] or human subjects post-pinealectomy [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/9\" class=\"abstract_t\">9</a>]. Tryptophan is first 5-hydroxylated by the enzyme tryptophan hydroxylase and then decarboxylated by the enzyme aromatic L-amino acid decarboxylase to form 5-hydroxytryptamine, or serotonin (<a href=\"image.htm?imageKey=ENDO%2F77541\" class=\"graphic graphic_figure graphicRef77541 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/7\" class=\"abstract_t\">7</a>].</p><p>During daylight hours, the serotonin in pinealocytes tends to be stored and unavailable to monoamine oxidase and the melatonin-forming enzymes that would otherwise act on it. With the onset of darkness, postganglionic sympathetic outflow to the pineal increases, and the consequent release of norepinephrine onto pinealocytes causes stored serotonin to become accessible for intracellular metabolism. At the same time, the norepinephrine activates the enzymes that convert serotonin to melatonin, especially serotonin-N-acetyltransferase (SNAT) [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/10\" class=\"abstract_t\">10</a>], but also hydroxyindole-O-methyltransferase (HIOMT) [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Consequently, pineal melatonin levels rise many-fold [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/13\" class=\"abstract_t\">13</a>]. Pineal levels of the corresponding deaminated and O-methylated metabolite of serotonin, 5-methoxytryptophol, also rise [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/14\" class=\"abstract_t\">14</a>], even though formation of this compound is independent of SNAT. This suggests that the daily rhythm in pineal SNAT activity is not the cause of the rhythm in melatonin synthesis, as has sometimes been proposed.</p><p>Melatonin then diffuses out of the pineal gland and into the blood stream and cerebrospinal fluid [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/15\" class=\"abstract_t\">15</a>], rapidly raising its plasma concentrations from approximately 2 to 10 <span class=\"nowrap\">pg/mL</span> (8.61 to 43.05 <span class=\"nowrap\">pmol/L)</span> to 100 to 200 <span class=\"nowrap\">pg/mL</span> (430 to 861 <span class=\"nowrap\">pmol/L)</span> [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/1\" class=\"abstract_t\">1</a>]. Melatonin is highly lipid soluble because both of the ionizable groups in serotonin, the hydroxyl and the amine, have been blocked by its O-methylation and N-acetylation. Thus, it diffuses freely across cell membranes, including those of the blood-brain barrier [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/16\" class=\"abstract_t\">16</a>], and travels in the blood largely bound to albumin [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/17\" class=\"abstract_t\">17</a>].</p><p>Most of the melatonin in the circulation is inactivated in the liver, where it is first oxidized to 6-OH-melatonin by a P450-dependent microsomal oxidase and then largely conjugated to sulfate or glucuronide before being excreted into the urine or feces [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/18\" class=\"abstract_t\">18</a>]. Approximately 2 to 3 percent of the circulating melatonin is excreted unchanged into the urine or the saliva, enabling measurements of urinary or salivary melatonin to be used as rough estimates of plasma melatonin concentrations. Salivary melatonin levels apparently correspond to those of the 25 to 30 percent of blood melatonin that is not bound to albumin. Salivary melatonin measurements are not widely used.</p><p>Studies using radioactively labeled melatonin have identified three probable melatonin receptors, two of which have been cloned using human sources [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/19\" class=\"abstract_t\">19</a>]. These macromolecules are concentrated, respectively, within the suprachiasmatic nucleus (SCN) of the hypothalamus, the pars tuberalis of the pituitary, and cardiac blood vessels (MT1); the retina and hippocampus (MT2); and in kidney, brain, and various peripheral organs (MT3). Their affinities for melatonin are enhanced in the presence of several G-proteins.</p><p>The MT1 receptors in the SCN allow melatonin to inhibit the firing of SCN neurons during the nighttime, an action that might contribute to melatonin's sleep-promoting effects. The SCN's MT2 receptors apparently mediate melatonin's effects on the SCN's own circadian rhythms.</p><p>Melatonin's MT1 and MT2 receptors are highly susceptible to &quot;desensitization,&quot; their activity decreasing markedly after exposure to supranormal concentrations of the hormone [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/20,21\" class=\"abstract_t\">20,21</a>]. This is relevant to the prolonged use of high melatonin doses to promote sleep, particularly among older adults with insomnia who might inadvertently purchase excessively large doses of the hormone.</p><p class=\"headingAnchor\" id=\"H14100125\"><span class=\"h2\">Circadian rhythm</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In all mammals examined thus far, melatonin secretion manifests a similar circadian rhythm, with plasma and urine concentrations low during daylight, ascending after the onset of darkness, peaking in the middle of the night between 11 PM and 3 AM, and then falling sharply before the time of light onset [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/1\" class=\"abstract_t\">1</a>]. It should be noted that high nocturnal plasma melatonin concentrations are characteristic of both diurnally active species (like humans), in which the high levels promote sleep onset and maintenance, and nocturnally active ones (like rats), in which melatonin has no obvious relationship to sleep.</p><p>While this rhythm normally is tightly entrained to the environmental light cycle, it does persist when people are placed for a few days in a dark room [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/22\" class=\"abstract_t\">22</a>] and, as described above, does not immediately phase shift when the light schedule is altered [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/2\" class=\"abstract_t\">2</a>], indicating that it is not simply generated by the light-dark cycle but also by cyclic endogenous signals, probably arising in the SCN. Signals originating in the retina or the SCN reach the pineal via a retinohypothalamic tract, the superior cervical ganglia, and postganglionic sympathetic fibers that re-enter the cranial cavity [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/23,24\" class=\"abstract_t\">23,24</a>]. In contrast, light has no known direct effects on pineal melatonin synthesis in humans and other mammals.</p><p>The ability of exogenous melatonin to synchronize and to shift the phases of various human circadian rhythms is generally accepted. In studies of healthy volunteers, 0.5 mg of pure melatonin [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/25\" class=\"abstract_t\">25</a>] or 0.05 mg of melatonin in corn oil (which causes earlier peaks in, and the more rapid disappearance of, elevated plasma melatonin concentrations) was able to advance the onset of nocturnal melatonin secretion when administered at 5 PM, and larger doses caused greater phase advances [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/26\" class=\"abstract_t\">26</a>]. In addition, melatonin was able to shift the core body temperature rhythm; however, a statistically significant effect was found only with doses &ge;0.5 mg. These doses increased plasma melatonin concentrations well above the upper limits of normal (&gt;1327 <span class=\"nowrap\">pg/mL</span> [5712 <span class=\"nowrap\">pmol/L])</span> [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/26\" class=\"abstract_t\">26</a>], suggesting that this may not be a physiologic effect.</p><p class=\"headingAnchor\" id=\"H530927275\"><span class=\"h2\">Potential role in cyclic disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Besides its iconic circadian rhythm, plasma melatonin concentrations have a seasonal (or circannual) rhythm, with higher levels in the <span class=\"nowrap\">fall/winter,</span> when nights are longer, and lower levels in the spring and summer [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/27-29\" class=\"abstract_t\">27-29</a>]. This has led some to propose that the annual rhythms in peak melatonin levels, or in their duration each night, may play a role in the pathophysiology of neurobehavioral diseases like multiple sclerosis (MS) and seasonal affective disorder (SAD), For example, the frequency of relapses in MS is significantly lower in fall and winter, when melatonin levels are highest [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/29-31\" class=\"abstract_t\">29-31</a>], and SAD, also termed &quot;winter blues,&quot; is identified in patients by its annual presentation in fall and winter [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Plasma concentrations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Plasma melatonin concentration reflects:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The amount secreted by the pineal gland (and, conceivably, the other organs described above)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The influx of melatonin into tissues when its plasma concentrations are high and efflux from them when plasma concentrations are low</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Its destruction in the liver</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Its secretion into such body fluids as urine and saliva</p><p/><p>Although it has been claimed that certain foods contain melatonin (wine, tomatoes), there is no evidence using specific assay techniques that food is a source of melatonin or that food sources increase plasma melatonin concentrations.</p><p>Usually, the principal factor affecting plasma melatonin concentration is its rate of secretion, which varies with the circadian rhythm and with age. Diet does not affect melatonin concentrations. (See <a href=\"#H14100125\" class=\"local\">'Circadian rhythm'</a> above and <a href=\"#H11\" class=\"local\">'Age'</a> below.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Age</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Melatonin secretion by the human pineal varies markedly with age. Melatonin secretion starts during the third or fourth months of life, coincident with the consolidation of sleeping at nighttime [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/33\" class=\"abstract_t\">33</a>]. It then increases rapidly, causing nocturnal melatonin concentrations to peak at ages one to three years, then declines slightly to a plateau that persists throughout early adulthood (<a href=\"image.htm?imageKey=ENDO%2F78560\" class=\"graphic graphic_figure graphicRef78560 \">figure 2</a>).</p><p>Nocturnal melatonin secretion then starts a marked continuing decline in most people, with peak nocturnal concentrations in 70 year olds being only a quarter or less of what they are in young adults (<a href=\"image.htm?imageKey=ENDO%2F78560\" class=\"graphic graphic_figure graphicRef78560 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/3,34\" class=\"abstract_t\">3,34</a>]. This decline may reflect the progressive, age-related calcification of the pineal gland and its resulting loss of secretory tissue. Obviously, one strategy in using supplemental melatonin is to administer it to older adults with age-associated insomnia in doses just sufficient to compensate for this age-related decline.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Effects of drugs or light</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nocturnal melatonin concentrations can also be affected by drugs that interfere with the transmission of neurotransmitter signals to pineal cells (like <a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a>, a beta-blocking agent [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/35\" class=\"abstract_t\">35</a>]) or those that inhibit melatonin's metabolism (like 8-methoxypsoralen [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/36\" class=\"abstract_t\">36</a>]) and by a few drugs that lack clear links to melatonin's synthesis or metabolism (eg, caffeine [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/37\" class=\"abstract_t\">37</a>], ethanol [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/38,39\" class=\"abstract_t\">38,39</a>]).</p><p>Nocturnal melatonin secretion is also suppressed by a relatively dim 100 to 200 lux when pupils are dilated [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/22,40,41\" class=\"abstract_t\">22,40,41</a>]. The most potent wavelength for suppressing melatonin secretion appears to be 446 to 477 nm, which differs from the peak absorbances of the photopigments for vision [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/42\" class=\"abstract_t\">42</a>].</p><p>Prolonged use of portable light-emitting devices (laptops, tablets, smartphones) before bedtime can have a negative impact on melatonin secretion, circadian rhythms, and sleep. One study compared the effects of reading an electronic book illuminated by a light-emitting device (LE-ebook) versus a printed book (by reflected light) for four hours prior to bedtime for five consecutive nights [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/43\" class=\"abstract_t\">43</a>]. Subjects in the LE-ebook group had suppressed melatonin concentrations in the early part of the night, a delayed endogenous circadian melatonin phase, felt less sleepy before bed, took longer to fall asleep, and reported feeling sleepier the following morning. These observations suggest that evening use of light-emitting devices may contribute to phase delays in the circadian clock and difficulty initiating sleep.</p><p class=\"headingAnchor\" id=\"H441449730\"><span class=\"h3\">Patients with nocturnal hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While sleeping at night, the blood pressure normally falls by approximately 15 percent from daytime values. Patients in whom this reduction does not occur are considered to have nocturnal hypertension, which has been associated with an excess risk of cardiovascular disease. (See <a href=\"topic.htm?path=ambulatory-and-home-blood-pressure-monitoring-and-white-coat-hypertension-in-adults#H10\" class=\"medical medical_review\">&quot;Ambulatory and home blood pressure monitoring and white coat hypertension in adults&quot;, section on 'Nocturnal blood pressure and nondippers'</a>.)</p><p>Two observations suggest that melatonin plays a role in nocturnal blood pressure regulation:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The normal nighttime surge in serum melatonin concentration may be blunted in patients with nocturnal hypertension [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Melatonin administration appears to lower blood pressure, particularly at night [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/45-48\" class=\"abstract_t\">45-48</a>].</p><p/><p>Although exogenous melatonin may have a modest effect on nocturnal blood pressure, we do not currently recommend its use for this indication, since there are no data showing improved outcomes.</p><p class=\"headingAnchor\" id=\"H722736508\"><span class=\"h1\">MELATONIN PREPARATIONS</span></p><p class=\"headingAnchor\" id=\"H441449287\"><span class=\"h2\">Regulatory issues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Melatonin products are regulated differently in many countries [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/49\" class=\"abstract_t\">49</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the United States, melatonin falls under the US Food and Drug Administration (FDA)'s Dietary Health and Education Act as a &quot;dietary supplement.&quot; It can be purchased in any dose without a prescription.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the European Union, melatonin has been evaluated by an official regulatory agency, the European Food Safety Authority (EFSA), for use in reducing sleep latency, the time it takes for normal sleepers or people with insomnia to fall asleep (at bedtime or after a nocturnal awakening) [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/50\" class=\"abstract_t\">50</a>]. Based on the evidence provided in all three of the statistically valid published meta-analyses [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/51-53\" class=\"abstract_t\">51-53</a>], the agency concluded that there exists &quot;a cause and effect relationship between the consumption of melatonin and a reduction of sleep onset latency&quot; and that &quot;in order to obtain the claimed effect, 1 mg of melatonin should be consumed close to bedtime&quot; [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/50\" class=\"abstract_t\">50</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In Canada, melatonin is included in the Natural Health Products Directorate of Health Canada and is available for sale, once preparations meet the licensing, manufacturing, labeling, and safety standards.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In Australia, melatonin is an unregistered product under the Therapeutic Goods Administration. With a prescription, it can be imported for use under the Personal Import Scheme.</p><p/><p>Of note is that in situations where the sale of melatonin is not regulated, very high doses can be sold, and preparations may contain additives that have their own pharmacologic actions and potential side effects. Occasional claims to the contrary notwithstanding, apparently all of the melatonin sold in the United States is of synthetic origin.</p><p class=\"headingAnchor\" id=\"H14099669\"><span class=\"h2\">Over the counter</span></p><p class=\"headingAnchor\" id=\"H722735623\"><span class=\"h3\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, in the United States, melatonin is considered a &quot;dietary supplement&quot; and can therefore be purchased in any dose without a prescription. Exogenous melatonin administration appears to have two effects like those occurring physiologically with nocturnal melatonin secretion: the promotion of sleep onset and maintenance [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/51-71\" class=\"abstract_t\">51-71</a>] and the phase shifting of circadian rhythms, including the rhythm in melatonin itself [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/25\" class=\"abstract_t\">25</a>]. Both have been shown to be produced by physiologic doses (ie, 0.1 to 0.3 mg for sleep and 0.3 to 0.5 mg for phase shifting, doses which raise daytime plasma melatonin levels into the normal nocturnal range observed in young adults). We therefore suggest the use of lower, more physiologic doses of melatonin, particularly in older adults (<a href=\"image.htm?imageKey=ENDO%2F64467\" class=\"graphic graphic_figure graphicRef64467 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/72\" class=\"abstract_t\">72</a>]. When preparations providing 0.3 to 0.5 mg are unavailable, the user can purchase 1.0 mg pills and cut them in half. </p><p>Although melatonin is relatively nontoxic, some marketed doses (1 to 10 mg) can elevate plasma concentrations to 3 to 60 times their normal peak values (<a href=\"image.htm?imageKey=ENDO%2F64467\" class=\"graphic graphic_figure graphicRef64467 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/54\" class=\"abstract_t\">54</a>]. Supraphysiologic concentrations of melatonin produce numerous biological effects, including daytime sleepiness, impaired mental and physical performance [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/73\" class=\"abstract_t\">73</a>], hypothermia [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/26\" class=\"abstract_t\">26</a>], and hyperprolactinemia [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/74\" class=\"abstract_t\">74</a>]. These effects are not observed with physiologic concentrations of melatonin.</p><p class=\"headingAnchor\" id=\"H722734423\"><span class=\"h3\">Bioavailability</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is considerable person-to-person variability in the bioavailability of melatonin. In one study using 0.5 mg oral doses, peak plasma melatonin concentrations among subjects varied over a greater than 10-fold range [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/75\" class=\"abstract_t\">75</a>]. Melatonin's bioavailability was relatively poor (10 to 56 percent), which the authors attributed to person-to-person differences in first-pass hepatic extraction. Perhaps reflecting such differences in hepatic function, older adult subjects in another study given a 0.3 mg oral dose of melatonin were found to exhibit considerably greater increments in plasma melatonin concentrations, with correspondingly greater variability, than young adults receiving that dose [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/76\" class=\"abstract_t\">76</a>].</p><p>These findings all suggest that, while a 0.3 mg dose given to young subjects during the daytime or to older adult insomniacs at night can, on average, produce normal nocturnal plasma melatonin concentrations, some individuals may need slightly more or significantly less melatonin to attain this effect on sleep.</p><p class=\"headingAnchor\" id=\"H30427363\"><span class=\"h3\">Prolonged-release formulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A prolonged-release (PR) prescription preparation of melatonin (melatonin PR 2 mg) is available in some countries but not the United States. In clinical trials in patients ages &ge;55 years with primary insomnia, this preparation was associated with improvements in sleep quality and latency, morning alertness, and health-related quality of life [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/77,78\" class=\"abstract_t\">77,78</a>].</p><p class=\"headingAnchor\" id=\"H722736473\"><span class=\"h2\">Melatonin agonists</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A synthetic melatonin agonist, <a href=\"topic.htm?path=ramelteon-drug-information\" class=\"drug drug_general\">ramelteon</a>, thought to activate MT1 and MT2 melatonin receptors selectively, is available in the United States for the treatment of chronic insomnia but not in the European Union, where it was denied approval. No data are available that directly compare the efficacies and toxicities of this compound with those of the much lower recommended dose (0.3 mg) of melatonin. The clinical use of melatonin agonists for the treatment of insomnia is discussed separately. (See <a href=\"topic.htm?path=treatment-of-insomnia-in-adults#H13\" class=\"medical medical_review\">&quot;Treatment of insomnia in adults&quot;, section on 'Melatonin agonists'</a>.)</p><p><a href=\"topic.htm?path=tasimelteon-drug-information\" class=\"drug drug_general\">Tasimelteon</a> is a second melatonin agonist that has been used for the treatment of insomnia and circadian rhythm sleep disorders, including non-24-hour sleep-wake disorder [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H109926124\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Despite the fact that melatonin is an unregulated drug in many countries and is often used in excessive doses, there does not appear to be a major pattern of side effects. One report described a search for reports of adverse effects with melatonin over 35 years [<a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/79\" class=\"abstract_t\">79</a>]. Of the nine studies reporting adverse effects, pharmacologic doses were used (1 to 36 mg), and the number of patients was not included. However, headache, confusion, and fragmented sleep were among the side effects reported. Dizziness, somnolence, nausea, and headache have been reported with the melatonin agonist <a href=\"topic.htm?path=ramelteon-drug-information\" class=\"drug drug_general\">ramelteon</a>. (See <a href=\"#H722736473\" class=\"local\">'Melatonin agonists'</a> above.)</p><p class=\"headingAnchor\" id=\"H14099730\"><span class=\"h1\">CLINICAL USES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical uses of melatonin include treatment of age-associated insomnia, jet lag, and shift work. These, as well as other potential uses of melatonin, are reviewed separately. (See <a href=\"topic.htm?path=treatment-of-insomnia-in-adults#H13\" class=\"medical medical_review\">&quot;Treatment of insomnia in adults&quot;, section on 'Melatonin agonists'</a> and <a href=\"topic.htm?path=jet-lag\" class=\"medical medical_review\">&quot;Jet lag&quot;</a> and <a href=\"topic.htm?path=complementary-and-alternative-therapies-for-cancer#H18\" class=\"medical medical_review\">&quot;Complementary and alternative therapies for cancer&quot;, section on 'Melatonin'</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=jet-lag-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Jet lag (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H31\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Melatonin production in humans has a pronounced circadian rhythm; nocturnal plasma melatonin concentrations are at least 10-fold higher than daytime concentrations. (See <a href=\"#H5\" class=\"local\">'Synthesis and metabolism'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The nocturnal rise in melatonin secretion plays an important role in the initiation and maintenance of sleep. The normal <span class=\"nowrap\">day/night</span> melatonin rhythm regulates the timing of other 24-hour rhythms. (See <a href=\"#H4\" class=\"local\">'Melatonin physiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nocturnal melatonin plasma concentrations decline with age; many older adult individuals develop age-associated insomnia (eg, waking up during the night, diminished sleep efficiency). Physiologic doses of melatonin may be beneficial for these individuals. (See <a href=\"#H11\" class=\"local\">'Age'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exposure to light suppresses the normal nocturnal rise in plasma melatonin concentrations. (See <a href=\"#H12\" class=\"local\">'Effects of drugs or light'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Melatonin is available in some countries, including the United States, as an over-the-counter preparation. We suggest the use of low, physiologic doses (0.1 to 0.5 mg) for insomnia or jet lag (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). High-dose preparations raise plasma melatonin concentrations to a supraphysiologic level and alter normal <span class=\"nowrap\">day/night</span> melatonin rhythms. (See <a href=\"#H722735623\" class=\"local\">'Dosing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Melatonin agonists are also now available for the management of insomnia and circadian rhythm sleep disorders. (See <a href=\"#H722736473\" class=\"local\">'Melatonin agonists'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recommendations for melatonin use for insomnia and jet lag are found separately. (See <a href=\"topic.htm?path=treatment-of-insomnia-in-adults#H13\" class=\"medical medical_review\">&quot;Treatment of insomnia in adults&quot;, section on 'Melatonin agonists'</a> and <a href=\"topic.htm?path=jet-lag\" class=\"medical medical_review\">&quot;Jet lag&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/1\" class=\"nounderline abstract_t\">Lynch HJ, Wurtman RJ, Moskowitz MA, et al. Daily rhythm in human urinary melatonin. Science 1975; 187:169.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/2\" class=\"nounderline abstract_t\">Lynch HJ, Jimerson DC, Ozaki Y, et al. Entrainment of rhythmic melatonin secretion in man to a 12-hour phase shift in the light/dark cycle. Life Sci 1978; 23:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/3\" class=\"nounderline abstract_t\">Waldhauser F, Weiszenbacher G, Frisch H, et al. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1984; 1:362.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/4\" class=\"nounderline abstract_t\">Srinivasan V, Spence WD, Pandi-Perumal SR, et al. Melatonin and human reproduction: shedding light on the darkness hormone. Gynecol Endocrinol 2009; 25:779.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/5\" class=\"nounderline abstract_t\">Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7:17.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/6\" class=\"nounderline abstract_t\">Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs 2009; 10:691.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/7\" class=\"nounderline abstract_t\">Axelrod J, Shein HM, Wurtman RJ. Stimulation of C14-melatonin synthesis from C14-tryptophan by noradrenaline in rat pineal in organ culture. Proc Natl Acad Sci U S A 1969; 62:544.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/8\" class=\"nounderline abstract_t\">Ozaki Y, Lynch HJ. Presence of melatonin in plasma and urine or pinealectomized rats. Endocrinology 1976; 99:641.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/9\" class=\"nounderline abstract_t\">Neuwelt EA, Lewy AJ. Disappearance of plasma melatonin after removal of a neoplastic pineal gland. N Engl J Med 1983; 308:1132.</a></li><li class=\"breakAll\">Klein DC. The pineal gland: A model of neuroendocrine regulation. In: The Hypothalamus, Reichlin S, Baldessarini RJ, Martin JB (Eds), Raven Press, New York 1978. p.303.</li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/11\" class=\"nounderline abstract_t\">WURTMAN RJ, AXELROD J, PHILLIPS LS. MELATONIN SYNTHESIS IN THE PINEAL GLAND: CONTROL BY LIGHT. Science 1963; 142:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/12\" class=\"nounderline abstract_t\">AXELROD J, WEISSBACH H. Enzymatic O-methylation of N-acetylserotonin to melatonin. Science 1960; 131:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/13\" class=\"nounderline abstract_t\">Lynch HJ. Diurnal oscillations in pineal melatonin content. Life Sci I 1971; 10:791.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/14\" class=\"nounderline abstract_t\">Skene DJ, Vivien-Roels B, Sparks DL, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 1990; 528:170.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/15\" class=\"nounderline abstract_t\">Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002; 143:84.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/16\" class=\"nounderline abstract_t\">WURTMAN RJ, AXELROD J, POTTER LT. THE UPTAKE OF H3-MELATONIN IN ENDOCRINE AND NERVOUS TISSUES AND THE EFFECTS OF CONSTANT LIGHT EXPOSURE. J Pharmacol Exp Ther 1964; 143:314.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/17\" class=\"nounderline abstract_t\">Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinology 1972; 91:1213.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/18\" class=\"nounderline abstract_t\">KOPIN IJ, PARE CM, AXELROD J, WEISSBACH H. 6-Hydroxylation, the major metabolic pathway for melatonin. Biochim Biophys Acta 1960; 40:377.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/19\" class=\"nounderline abstract_t\">Witt-Enderby PA, Bennett J, Jarzynka MJ, et al. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72:2183.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/20\" class=\"nounderline abstract_t\">Gerdin MJ, Masana MI, Rivera-Berm&uacute;dez MA, et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J 2004; 18:1646.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/21\" class=\"nounderline abstract_t\">Gerdin MJ, Masana MI, Dubocovich ML. Melatonin-mediated regulation of human MT(1) melatonin receptors expressed in mammalian cells. Biochem Pharmacol 2004; 67:2023.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/22\" class=\"nounderline abstract_t\">Lewy AJ, Wehr TA, Goodwin FK, et al. Light suppresses melatonin secretion in humans. Science 1980; 210:1267.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/23\" class=\"nounderline abstract_t\">WURTMAN RJ, AXELROD J, FISCHER JE. MELATONIN SYNTHESIS IN THE PINEAL GLAND: EFFECT OF LIGHT MEDIATED BY THE SYMPATHETIC NERVOUS SYSTEM. Science 1964; 143:1328.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/24\" class=\"nounderline abstract_t\">Klein DC, Moore RY. Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res 1979; 174:245.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/25\" class=\"nounderline abstract_t\">Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992; 9:380.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/26\" class=\"nounderline abstract_t\">Deacon S, Arendt J. Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res 1995; 688:77.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/27\" class=\"nounderline abstract_t\">Arendt J, Wirz-Justice A, Bradtke J, Kornemark M. Long-term studies on immunoreactive human melatonin. Ann Clin Biochem 1979; 16:307.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/28\" class=\"nounderline abstract_t\">Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336:186.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/29\" class=\"nounderline abstract_t\">Farez MF, Mascanfroni ID, M&eacute;ndez-Huergo SP, et al. Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Cell 2015; 162:1338.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/30\" class=\"nounderline abstract_t\">Jin Y, de Pedro-Cuesta J, S&ouml;derstr&ouml;m M, et al. Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci 2000; 181:56.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/31\" class=\"nounderline abstract_t\">Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 2014; 32:257.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/32\" class=\"nounderline abstract_t\">Rosenthal NE, Sack DA, Gillin JC, et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984; 41:72.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/33\" class=\"nounderline abstract_t\">Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab 1992; 75:367.</a></li><li class=\"breakAll\">Waldhauser F, Lynch HJ, Wurtman RJ. Melatonin in human body fluids: Clinical significance. In: The Pineal Gland (Comprehensive Endocrinology), Reiter RJ (Ed), Raven Press, New York 1984. p.345.</li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/35\" class=\"nounderline abstract_t\">Mayeda A, Mannon S, Hofstetter J, et al. Effects of indirect light and propranolol on melatonin levels in normal human subjects. Psychiatry Res 1998; 81:9.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/36\" class=\"nounderline abstract_t\">Garde E, Micic S, Knudsen K, et al. 8-methoxypsoralen increases daytime plasma melatonin levels in humans through inhibition of metabolism. Photochem Photobiol 1994; 60:475.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/37\" class=\"nounderline abstract_t\">Wright KP Jr, Badia P, Myers BL, et al. Caffeine and light effects on nighttime melatonin and temperature levels in sleep-deprived humans. Brain Res 1997; 747:78.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/38\" class=\"nounderline abstract_t\">R&ouml;jdmark S, Wikner J, Adner N, et al. Inhibition of melatonin secretion by ethanol in man. Metabolism 1993; 42:1047.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/39\" class=\"nounderline abstract_t\">Ekman AC, Lepp&auml;luoto J, Huttunen P, et al. Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study. J Clin Endocrinol Metab 1993; 77:780.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/40\" class=\"nounderline abstract_t\">Brainard GC, Rollag MD, Hanifin JP. Photic regulation of melatonin in humans: ocular and neural signal transduction. J Biol Rhythms 1997; 12:537.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/41\" class=\"nounderline abstract_t\">Aoki H, Yamada N, Ozeki Y, et al. Minimum light intensity required to suppress nocturnal melatonin concentration in human saliva. Neurosci Lett 1998; 252:91.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/42\" class=\"nounderline abstract_t\">Brainard GC, Hanifin JP, Greeson JM, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 2001; 21:6405.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/43\" class=\"nounderline abstract_t\">Chang AM, Aeschbach D, Duffy JF, Czeisler CA. Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness. Proc Natl Acad Sci U S A 2015; 112:1232.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/44\" class=\"nounderline abstract_t\">Jonas M, Garfinkel D, Zisapel N, et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003; 12:19.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/45\" class=\"nounderline abstract_t\">Arangino S, Cagnacci A, Angiolucci M, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol 1999; 83:1417.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/46\" class=\"nounderline abstract_t\">Burgess HJ, Sletten T, Savic N, et al. Effects of bright light and melatonin on sleep propensity, temperature, and cardiac activity at night. J Appl Physiol (1985) 2001; 91:1214.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/47\" class=\"nounderline abstract_t\">Cagnacci A, Cannoletta M, Renzi A, et al. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005; 18:1614.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/48\" class=\"nounderline abstract_t\">Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006; 119:898.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/49\" class=\"nounderline abstract_t\">Jansen SL, Forbes DA, Duncan V, Morgan DG. Melatonin for cognitive impairment. Cochrane Database Syst Rev 2006; :CD003802.</a></li><li class=\"breakAll\">European Food Safety Authority. Scientific opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to article 13(1) of regulation (EC) No 1924/2006. EFSA Journal 2011; 9:2241. http://www.efsa.europa.eu/en/efsajournal/doc/2241.pdf (Accessed on September 23, 2011).</li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/51\" class=\"nounderline abstract_t\">Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9:41.</a></li><li class=\"breakAll\">Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for treatment of sleep disorders. Summary, evidence report/technology assessment: Number 108. AHRQ Publication Number 05-E002-1, November 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epcsums/melatsum.htm (Accessed on September 23, 2011).</li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/53\" class=\"nounderline abstract_t\">Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005; 20:1151.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/54\" class=\"nounderline abstract_t\">Dollins AB, Zhdanova IV, Wurtman RJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 1994; 91:1824.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/55\" class=\"nounderline abstract_t\">Zhdanova IV, Wurtman RJ. Efficacy of melatonin as a sleep-promoting agent. J Biol Rhythms 1997; 12:644.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/56\" class=\"nounderline abstract_t\">Cramer H, Rudolph J, Consbruch U, Kendel K. On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharmacol 1974; 11:187.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/57\" class=\"nounderline abstract_t\">James SP, Mendelson WB, Sack DA, et al. The effect of melatonin on normal sleep. Neuropsychopharmacology 1987; 1:41.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/58\" class=\"nounderline abstract_t\">James SP, Sack DA, Rosenthal NE, Mendelson WB. Melatonin administration in insomnia. Neuropsychopharmacology 1990; 3:19.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/59\" class=\"nounderline abstract_t\">Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl) 1990; 100:222.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/60\" class=\"nounderline abstract_t\">Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet 1991; 337:1121.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/61\" class=\"nounderline abstract_t\">Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18:598.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/62\" class=\"nounderline abstract_t\">Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346:541.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/63\" class=\"nounderline abstract_t\">Wurtman RJ, Zhdanova I. Improvement of sleep quality by melatonin. Lancet 1995; 346:1491.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/64\" class=\"nounderline abstract_t\">Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57:552.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/65\" class=\"nounderline abstract_t\">Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl) 1996; 126:179.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/66\" class=\"nounderline abstract_t\">Zhdanova IV, Wurtman RJ, Morabito C, et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996; 19:423.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/67\" class=\"nounderline abstract_t\">Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 1997; 20:124.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/68\" class=\"nounderline abstract_t\">Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998; 21:52.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/69\" class=\"nounderline abstract_t\">Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86:4727.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/70\" class=\"nounderline abstract_t\">Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry 2000; 61:373.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/71\" class=\"nounderline abstract_t\">Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26:893.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/72\" class=\"nounderline abstract_t\">Vural EM, van Munster BC, de Rooij SE. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging 2014; 31:441.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/73\" class=\"nounderline abstract_t\">Atkinson G, Jones H, Edwards BJ, Waterhouse JM. Effects of daytime ingestion of melatonin on short-term athletic performance. Ergonomics 2005; 48:1512.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/74\" class=\"nounderline abstract_t\">Waldhauser F, Lieberman HR, Lynch HJ, et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol. Neuroendocrinology 1987; 46:125.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/75\" class=\"nounderline abstract_t\">Di WL, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med 1997; 336:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/76\" class=\"nounderline abstract_t\">Zhdanova IV, Wurtman RJ, Balcioglu A, et al. Endogenous melatonin levels and the fate of exogenous melatonin: age effects. J Gerontol A Biol Sci Med Sci 1998; 53:B293.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/77\" class=\"nounderline abstract_t\">Lyseng-Williamson KA. Melatonin prolonged release: in the treatment of insomnia in patients aged &ge;55 years. Drugs Aging 2012; 29:911.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/78\" class=\"nounderline abstract_t\">Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010; 8:51.</a></li><li><a href=\"https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin/abstract/79\" class=\"nounderline abstract_t\">Morera AL, Henry M, de La Varga M. [Safety in melatonin use]. Actas Esp Psiquiatr 2001; 29:334.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6634 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H31\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">OVERVIEW</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">MELATONIN PHYSIOLOGY</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Synthesis and metabolism</a></li><li><a href=\"#H14100125\" id=\"outline-link-H14100125\">Circadian rhythm</a></li><li><a href=\"#H530927275\" id=\"outline-link-H530927275\">Potential role in cyclic disorders</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Plasma concentrations</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Age</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Effects of drugs or light</a></li><li><a href=\"#H441449730\" id=\"outline-link-H441449730\">- Patients with nocturnal hypertension</a></li></ul></li></ul></li><li><a href=\"#H722736508\" id=\"outline-link-H722736508\">MELATONIN PREPARATIONS</a><ul><li><a href=\"#H441449287\" id=\"outline-link-H441449287\">Regulatory issues</a></li><li><a href=\"#H14099669\" id=\"outline-link-H14099669\">Over the counter</a><ul><li><a href=\"#H722735623\" id=\"outline-link-H722735623\">- Dosing</a></li><li><a href=\"#H722734423\" id=\"outline-link-H722734423\">- Bioavailability</a></li><li><a href=\"#H30427363\" id=\"outline-link-H30427363\">- Prolonged-release formulation</a></li></ul></li><li><a href=\"#H722736473\" id=\"outline-link-H722736473\">Melatonin agonists</a></li><li><a href=\"#H109926124\" id=\"outline-link-H109926124\">Adverse effects</a></li></ul></li><li><a href=\"#H14099730\" id=\"outline-link-H14099730\">CLINICAL USES</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H1118840704\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/6634|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/77541\" class=\"graphic graphic_figure\">- Metabolism of tryptophan</a></li><li><a href=\"image.htm?imageKey=ENDO/78560\" class=\"graphic graphic_figure\">- Nighttime serum melatonin</a></li><li><a href=\"image.htm?imageKey=ENDO/64467\" class=\"graphic graphic_figure\">- Mean serum melatonin</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=ambulatory-and-home-blood-pressure-monitoring-and-white-coat-hypertension-in-adults\" class=\"medical medical_review\">Ambulatory and home blood pressure monitoring and white coat hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=complementary-and-alternative-therapies-for-cancer\" class=\"medical medical_review\">Complementary and alternative therapies for cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=jet-lag\" class=\"medical medical_review\">Jet lag</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=jet-lag-the-basics\" class=\"medical medical_basics\">Patient education: Jet lag (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-insomnia-in-adults\" class=\"medical medical_review\">Treatment of insomnia in adults</a></li></ul></div></div>","javascript":null}